Long-term disease control in multiple myeloma by in-class transitioning: A commu...
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
3 Jul 2020
Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma
Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
3 Jul 2020
Treating acute lymphoblastic leukaemia in the era of COVID-19
Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
3 Jul 2020
Managing acute myeloid leukaemia during the COVID-19 pandemic
Dr Naval Daver - MD Anderson Cancer Center, Houston, USA
1 Jul 2020
Gut microbiome disturbance by antibiotic treatment early in life is sufficient t...
Dr Carolina Vicente-Dueñas - Institute of Biomedical Research of Salamanca, Sala...
30 Jun 2020
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with r...
Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA
30 Jun 2020
Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patient...
Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy
26 Jun 2020
Treating patients with multiple myeloma in the real world
Dr Ajai Chari and Prof Roman Hájek
26 Jun 2020
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine...
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
26 Jun 2020
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma
Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain
26 Jun 2020
Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients w...
Dr Naval Daver - MD Anderson Cancer Center, Houston, USA
26 Jun 2020
New CAR T therapy for relapsed and refractory ALL
Dr Claire Roddie - University College London, London, UK
25 Jun 2020
